Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$88.61 USD

88.61
2,531,645

+0.86 (0.98%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $88.50 -0.11 (-0.12%) 7:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Urmimala Biswas headshot

Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?

Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.

Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings

GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings

Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.

Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?

West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

Unveiling Edwards Lifesciences (EW) Q1 Outlook: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?

Universal Health's (UHS) Q1 results are expected to be aided by growing patient volumes and surgical cases, partly offset by increased expenses.

Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth

Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.

Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?

Humana's (HUM) first-quarter results are likely to reflect rising premiums and investment income.

Nalak Das headshot

5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings

We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.

Will High Medical Care Ratios Hurt Molina's (MOH) Q1 Earnings?

Molina's (MOH) first-quarter performance is likely to have been hurt by escalating medical care costs, partly offset by growing membership in all three businesses.

Will Low Patient Days Impact Community Health (CYH) Q1 Earnings?

Community Health's (CYH) first-quarter results are likely to reflect declining beds in services and adjusted admissions.

Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?

The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.

Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?

The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q1 Earnings?

Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

UnitedHealth Group (UNH) Tops on Q1 Earnings, Reaffirms EPS View

UnitedHealth Group (UNH) first-quarter earnings benefit from strong Optum and UnitedHealthcare business lines. Rising expenses partially offset the positives.

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.

ITGR vs. EW: Which Stock Should Value Investors Buy Now?

ITGR vs. EW: Which Stock Is the Better Value Option?

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.

Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS

Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.

What's in Store for Thermo Fisher (TMO) in Q1 Earnings?

Strength in Analytical Instrument and Laboratory Products and Services segments are likely to have driven Thermo Fisher's (TMO) first-quarter 2024 performance.

Will Elevance (ELV) Beat Q1 Earnings on Carelon Strength?

The first-quarter results of Elevance (ELV) are likely to reflect higher product revenues and Commercial Individual membership growth.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.